# RideNow Group, Inc.: financial statements, quarterly

RDNW · Nasdaq · CIK 1596961 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/rdnw.md) · [Financials](/companies/rdnw/financials.md) · [Filings](/companies/rdnw/filings.md) · [Insiders](/companies/rdnw/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/rdnw/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [338](/filings/0001596961-24-000106.md) | [311 d](/filings/0001596961-25-000024.md) | [308](/filings/0001596961-25-000039.md) | [337](/filings/0001596961-25-000066.md) | [295](/filings/0001596961-25-000101.md) | [270 d](/filings/0001596961-26-000015.md) | [245](/filings/0001628280-26-035184.md) | [300](/filings/0001628280-26-055737.md) | [281](/filings/0001596961-25-000101.md) | [257 d](/filings/0001596961-26-000015.md) | [260](/filings/0001628280-26-035184.md) | [297](/filings/0001628280-26-055737.md) |
| Cost of revenue | $m | [246](/filings/0001596961-24-000106.md) | [240 d](/filings/0001596961-25-000024.md) | [225](/filings/0001596961-25-000039.md) | [247](/filings/0001596961-25-000066.md) | [221](/filings/0001596961-25-000101.md) | [202 d](/filings/0001596961-26-000015.md) | [178](/filings/0001628280-26-035184.md) | [216](/filings/0001628280-26-055737.md) | [205](/filings/0001596961-25-000101.md) | [186 d](/filings/0001596961-26-000015.md) | [189](/filings/0001628280-26-035184.md) | [212](/filings/0001628280-26-055737.md) |
| Gross profit | $m | [92.0](/filings/0001596961-24-000106.md) | [71.2 d](/filings/0001596961-25-000024.md) | [82.6](/filings/0001596961-25-000039.md) | [89.9](/filings/0001596961-25-000066.md) | [74.3](/filings/0001596961-25-000101.md) | [67.5 d](/filings/0001596961-26-000015.md) | [67.2](/filings/0001628280-26-035184.md) | [83.9](/filings/0001628280-26-055737.md) | [76.0](/filings/0001596961-25-000101.md) | [70.9 d](/filings/0001596961-26-000015.md) | [71.6](/filings/0001628280-26-035184.md) | [84.8](/filings/0001628280-26-055737.md) |
| Research and development | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Selling, general and administrative | $m | [85.0](/filings/0001596961-24-000106.md) | [75.7 d](/filings/0001596961-25-000024.md) | [73.9](/filings/0001596961-25-000039.md) | [71.4](/filings/0001596961-25-000066.md) | [65.9](/filings/0001596961-25-000101.md) | [64.2 d](/filings/0001596961-26-000015.md) | [61.1](/filings/0001628280-26-035184.md) | [66.7](/filings/0001628280-26-055737.md) | [64.4](/filings/0001596961-25-000101.md) | [64.1 d](/filings/0001596961-26-000015.md) | [62.1](/filings/0001628280-26-035184.md) | [65.0](/filings/0001628280-26-055737.md) |
| Operating income | $m | [(0.2)](/filings/0001596961-24-000106.md) | [(69.4) d](/filings/0001596961-25-000024.md) | [5.2](/filings/0001596961-25-000039.md) | [15.4](/filings/0001596961-25-000066.md) | [5.3](/filings/0001596961-25-000101.md) | [(41.1) d](/filings/0001596961-26-000015.md) | [3.8](/filings/0001628280-26-035184.md) | [(18.8)](/filings/0001628280-26-055737.md) | [9.4](/filings/0001596961-25-000101.md) | [5.4 d](/filings/0001596961-26-000015.md) | [7.6](/filings/0001628280-26-035184.md) | [17.9](/filings/0001628280-26-055737.md) |
| Interest expense | $m | [19.8](/filings/0001596961-23-000047.md) | [21.4 d](/filings/0001596961-24-000021.md) | [16.1](/filings/0001596961-24-000053.md) | [16.2](/filings/0001596961-24-000081.md) | [16.6](/filings/0001596961-24-000106.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [(3.5)](/filings/0001596961-24-000106.md) | [69.0 d](/filings/0001596961-25-000024.md) | [(0.3)](/filings/0001596961-25-000039.md) | [(0.1)](/filings/0001596961-25-000066.md) | [0.0](/filings/0001596961-25-000101.md) | [0.2 d](/filings/0001596961-26-000015.md) | [0.1](/filings/0001628280-26-035184.md) | [0.1](/filings/0001628280-26-055737.md) | [0.1](/filings/0001596961-25-000101.md) | [0.0 d](/filings/0001596961-26-000015.md) | [0.1](/filings/0001628280-26-035184.md) | [0.1](/filings/0001628280-26-055737.md) |
| Net income | $m | [(16.5)](/filings/0001596961-24-000106.md) | [(169) d](/filings/0001596961-25-000024.md) | [(10.3)](/filings/0001596961-25-000039.md) | [(0.7)](/filings/0001596961-25-000066.md) | [(11.2)](/filings/0001596961-25-000101.md) | [(56.4) d](/filings/0001596961-26-000015.md) | [(9.7)](/filings/0001628280-26-035184.md) | [(32.2)](/filings/0001628280-26-055737.md) | [(4.1)](/filings/0001596961-25-000101.md) | [(6.4) d](/filings/0001596961-26-000015.md) | [(4.3)](/filings/0001628280-26-035184.md) | [6.5](/filings/0001628280-26-055737.md) |
| Diluted EPS | $ per share | [(0.99)](/filings/0001596961-24-000106.md) | not reported | [(0.29)](/filings/0001596961-25-000039.md) | [(0.02)](/filings/0001596961-25-000066.md) | [(0.32)](/filings/0001596961-25-000101.md) | not reported | [(0.26)](/filings/0001628280-26-035184.md) | [(0.85)](/filings/0001628280-26-055737.md) | [(0.11)](/filings/0001596961-25-000101.md) | not reported | [(0.11)](/filings/0001628280-26-035184.md) | [0.16](/filings/0001628280-26-055737.md) |
| Basic EPS | $ per share | [(0.99)](/filings/0001596961-24-000106.md) | not reported | [(0.29)](/filings/0001596961-25-000039.md) | [(0.02)](/filings/0001596961-25-000066.md) | [(0.32)](/filings/0001596961-25-000101.md) | not reported | [(0.26)](/filings/0001628280-26-035184.md) | [(0.85)](/filings/0001628280-26-055737.md) | [(0.11)](/filings/0001596961-25-000101.md) | not reported | [(0.11)](/filings/0001628280-26-035184.md) | [0.17](/filings/0001628280-26-055737.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: not reported
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [41.4](/filings/0001596961-24-000106.md) | [58.9](/filings/0001596961-25-000024.md) | [50.3](/filings/0001596961-25-000039.md) | [58.1](/filings/0001596961-25-000066.md) | [50.1](/filings/0001596961-25-000101.md) | [85.3](/filings/0001596961-26-000015.md) | [41.1](/filings/0001628280-26-035184.md) | [44.7](/filings/0001628280-26-055737.md) | [35.4](/filings/0001596961-25-000101.md) | [29.5](/filings/0001628280-26-055737.md) | [30.2](/filings/0001628280-26-035184.md) | [46.7](/filings/0001628280-26-055737.md) |
| Current assets | $m | [479](/filings/0001596961-23-000047.md) | [481](/filings/0001596961-25-000024.md) | [454](/filings/0001596961-24-000053.md) | [457](/filings/0001596961-24-000081.md) | [395](/filings/0001596961-24-000106.md) | [371](/filings/0001596961-26-000015.md) | [358](/filings/0001596961-25-000039.md) | [366](/filings/0001596961-25-000066.md) | [358](/filings/0001596961-25-000101.md) | [335](/filings/0001628280-26-055737.md) | [385](/filings/0001628280-26-035184.md) | [404](/filings/0001628280-26-055737.md) |
| Total assets | $m | [1,059](/filings/0001596961-23-000047.md) | [926](/filings/0001596961-25-000024.md) | [899](/filings/0001596961-24-000053.md) | [896](/filings/0001596961-24-000081.md) | [831](/filings/0001596961-24-000106.md) | [755](/filings/0001596961-26-000015.md) | [739](/filings/0001596961-25-000039.md) | [712](/filings/0001596961-25-000066.md) | [699](/filings/0001596961-25-000101.md) | [674](/filings/0001628280-26-055737.md) | [722](/filings/0001628280-26-035184.md) | [736](/filings/0001628280-26-055737.md) |
| Current liabilities | $m | [384](/filings/0001596961-23-000047.md) | [395](/filings/0001596961-25-000024.md) | [412](/filings/0001596961-24-000053.md) | [408](/filings/0001596961-24-000081.md) | [352](/filings/0001596961-24-000106.md) | [324](/filings/0001596961-26-000015.md) | [316](/filings/0001596961-25-000039.md) | [317](/filings/0001596961-25-000066.md) | [320](/filings/0001596961-25-000101.md) | [297](/filings/0001628280-26-055737.md) | [346](/filings/0001628280-26-035184.md) | [354](/filings/0001628280-26-055737.md) |
| Total liabilities | $m | [884](/filings/0001596961-23-000047.md) | [821](/filings/0001596961-25-000024.md) | [806](/filings/0001596961-24-000053.md) | [803](/filings/0001596961-24-000081.md) | [747](/filings/0001596961-24-000106.md) | [719](/filings/0001596961-26-000015.md) | [712](/filings/0001596961-25-000039.md) | [717](/filings/0001596961-25-000066.md) | [706](/filings/0001596961-25-000101.md) | [686](/filings/0001628280-26-055737.md) | [738](/filings/0001628280-26-035184.md) | [745](/filings/0001628280-26-055737.md) |
| Long-term debt | $m | not reported | [239](/filings/0001596961-25-000024.md) | [206](/filings/0001596961-24-000053.md) | [209](/filings/0001596961-24-000081.md) | [210](/filings/0001596961-24-000106.md) | [212](/filings/0001596961-26-000015.md) | [215](/filings/0001596961-25-000039.md) | [218](/filings/0001596961-25-000066.md) | [207](/filings/0001596961-25-000101.md) | [207](/filings/0001628280-26-055737.md) | [210](/filings/0001628280-26-035184.md) | [212](/filings/0001628280-26-055737.md) |
| Current portion of debt | $m | not reported | [35.6](/filings/0001596961-25-000024.md) | [39.2](/filings/0001596961-24-000053.md) | [39.2](/filings/0001596961-24-000081.md) | [39.2](/filings/0001596961-24-000106.md) | [39.1](/filings/0001596961-26-000015.md) | [0.4](/filings/0001596961-25-000039.md) | [0.4](/filings/0001596961-25-000066.md) | [0.4](/filings/0001596961-25-000101.md) | [0.4](/filings/0001628280-26-035184.md) | [0.9](/filings/0001628280-26-035184.md) | not reported |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [175](/filings/0001596961-24-000106.md) | [106](/filings/0001596961-26-000015.md) | [92.7](/filings/0001596961-25-000066.md) | [93.4](/filings/0001596961-25-000101.md) | [83.3](/filings/0001596961-25-000101.md) | [36.7](/filings/0001628280-26-055737.md) | [26.9](/filings/0001628280-26-055737.md) | [(4.7)](/filings/0001628280-26-055737.md) | [(6.9)](/filings/0001596961-25-000101.md) | [(12.5)](/filings/0001628280-26-055737.md) | [(16.2)](/filings/0001628280-26-055737.md) | [(8.9)](/filings/0001628280-26-055737.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(12.9) d](/filings/0001596961-24-000106.md) | [(20.4) d](/filings/0001596961-25-000024.md) | [17.0](/filings/0001596961-25-000039.md) | [12.2 d](/filings/0001596961-25-000066.md) | [39.4 d](/filings/0001596961-25-000101.md) | [30.8 d](/filings/0001596961-26-000015.md) | [(6.9)](/filings/0001628280-26-035184.md) | [10.9 d](/filings/0001628280-26-055737.md) | [11.5 d](/filings/0001596961-25-000101.md) | [0.4 d](/filings/0001596961-26-000015.md) | [(27.6)](/filings/0001628280-26-035184.md) | [(0.1) d](/filings/0001628280-26-055737.md) |
| Capital expenditure | $m | [1.8 d](/filings/0001596961-24-000106.md) | [5.9 d](/filings/0001596961-25-000024.md) | [0.6](/filings/0001596961-25-000039.md) | [0.4 d](/filings/0001596961-25-000066.md) | [0.6 d](/filings/0001596961-25-000101.md) | [0.4 d](/filings/0001596961-26-000015.md) | [0.5](/filings/0001628280-26-035184.md) | [2.4 d](/filings/0001628280-26-055737.md) | [2.1 d](/filings/0001596961-25-000101.md) | [0.6 d](/filings/0001596961-26-000015.md) | [0.6](/filings/0001628280-26-035184.md) | [1.5 d](/filings/0001628280-26-055737.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations, us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [16.1](/filings/0001596961-23-000047.md) | [16.2](/filings/0001596961-24-000053.md) | [16.5](/filings/0001596961-24-000081.md) | [16.7](/filings/0001596961-24-000106.md) | [35.1](/filings/0001596961-25-000039.md) | [35.2](/filings/0001596961-25-000066.md) | [35.3](/filings/0001596961-25-000101.md) | [37.8](/filings/0001628280-26-035184.md) | [37.9](/filings/0001628280-26-055737.md) | [38.1](/filings/0001596961-25-000101.md) | [38.4](/filings/0001628280-26-035184.md) | [39.0](/filings/0001628280-26-055737.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 2,191,633 at 2020-11-13, from the cover of the [10-Q filed 2020-11-16](/filings/0001654954-20-012496.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:43 ET. No prices; not investment advice.